Windtree Therapeutics Files 8-K Report
Ticker: WINTW · Form: 8-K · Filed: Jan 8, 2025 · CIK: 946486
| Field | Detail |
|---|---|
| Company | Windtree Therapeutics Inc /De/ (WINTW) |
| Form Type | 8-K |
| Filed Date | Jan 8, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, filing, financials
TL;DR
Windtree Therapeutics filed an 8-K. Check for updates.
AI Summary
On January 8, 2025, Windtree Therapeutics, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating updates or disclosures related to the company's financial status and significant occurrences. No specific dollar amounts or new material events were detailed in the provided excerpt.
Why It Matters
This filing signals that Windtree Therapeutics is providing updates to the SEC, which could contain material information for investors regarding the company's operations or financial health.
Risk Assessment
Risk Level: low — The filing is a standard 8-K report with no immediate indication of negative events or significant financial distress in the provided text.
Key Players & Entities
- WINDTREE THERAPEUTICS INC /DE/ (company) — Registrant
- 0000946486 (company) — Central Index Key
- 2600 KELLY ROAD (company) — Business Address
- Warrington (company) — City
- Pennsylvania (company) — State
- 18976 (company) — ZIP Code
- 2154889300 (company) — Business Phone
- DISCOVERY LABORATORIES INC /DE/ (company) — Former Company Name
- ANSAN PHARMACEUTICALS INC (company) — Former Company Name
- ANSAN INC (company) — Former Company Name
FAQ
What is the primary purpose of this 8-K filing?
The filing is primarily for "Other Events" and "Financial Statements and Exhibits," indicating updates or disclosures related to the company's financial status and significant occurrences.
When was this 8-K report filed?
The report was filed on January 8, 2025.
What is Windtree Therapeutics' state of incorporation?
Windtree Therapeutics, Inc. is incorporated in Delaware.
What is the company's principal executive office address?
The principal executive offices are located at 2600 Kelly Road, Suite 100, Warrington, Pennsylvania 18976.
Has Windtree Therapeutics undergone name changes in the past?
Yes, the company was formerly known as Discovery Laboratories, Inc. /DE/, Ansan Pharmaceuticals Inc., and Ansan Inc.
Filing Stats: 455 words · 2 min read · ~2 pages · Grade level 10.7 · Accepted 2025-01-08 08:05:12
Key Financial Figures
- $0.001 — h registered Common Stock , par value $0.001 per share WINT The Nasdaq Capital Ma
Filing Documents
- wint20250107_8k.htm (8-K) — 28KB
- ex_763168.htm (EX-99.1) — 12KB
- 0001437749-25-000675.txt ( ) — 177KB
- wint-20250108.xsd (EX-101.SCH) — 3KB
- wint-20250108_def.xml (EX-101.DEF) — 12KB
- wint-20250108_lab.xml (EX-101.LAB) — 15KB
- wint-20250108_pre.xml (EX-101.PRE) — 12KB
- wint20250107_8k_htm.xml (XML) — 3KB
01
Item 8.01 Other Events On January 8, 2025, Windtree Therapeutics, Inc. (the "Company") issued a press release announcing that the Company has a new corporate strategy. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Financial Statements and Exhibits
Financial Statements and Exhibits (d) Exhibits The following exhibits are being filed herewith: Exhibit No. Document 99.1 Press Release of Windtree Therapeutics, Inc., dated January 8, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Windtree Therapeutics, Inc. By: /s/ Jed Latkin Name: Jed Latkin Title: President and Chief Executive Officer Date: January 8, 2025